Literature DB >> 3279497

Pharmacokinetics and efficacy of the new quinolones in infections of the eye, ear, nose, and throat.

M Barza1.   

Abstract

A review of published data indicates that the new quinolones readily penetrate the tissues and secretions of the upper respiratory tract. The concentrations of ciprofloxacin and ofloxacin in tonsillar tissue and the concentrations of ofloxacin in the mucosa of the paranasal sinuses generally exceeded the peak concentrations of these agents in serum after oral administration of the drugs. Good penetration was noted for ciprofloxacin into nasal secretions, ofloxacin into tears, and various quinolones into saliva. Penetration into ocular humors appears to be moderate. Reports in English concerning clinical trials of the new fluoroquinolones in the treatment of infections of the eyes, ears, nose, and throat are sparse, but a number of studies of ofloxacin have been published in Japanese. The data suggest that the new quinolones may be useful for the treatment of acute sinusitis and chronic suppurative otitis media. However, studies comparing these agents with more established drugs and using carefully defined criteria for diagnosis and for evaluation of the response to treatment are needed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3279497     DOI: 10.1093/clinids/10.supplement_1.s241

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  3 in total

1.  Clinical experiences with ofloxacin sequential therapy in chronic ear infections.

Authors:  W Heppt; H Lutz
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

Review 2.  Use of quinolones for treatment of ear and eye infections.

Authors:  M Barza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

3.  Pharmacokinetics of ofloxacin in serum and vitreous humor of albino and pigmented rabbits.

Authors:  R J Perkins; W Liu; G Drusano; A Madu; M Mayers; C Madu; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.